CA-COGNIGY
1.9.2020 14:02:45 CEST | Business Wire | Press release
Cognigy, a global leader in Conversational AI today announced the launch of its latest release, Cognigy.AI v4, which simplifies the creation of virtual agents across the enterprise.
Cognigy.AI v4 enables users of all skill levels, from non-technical users to advanced conversational designers and developers, to build advanced virtual agents with greater ease and speed. New plug and play extensions allow business users to integrate with backend systems and deploy securely. Multi-lingual virtual agents bridge language barriers by connecting business logic with widely used integrations, including leading Contact Center solutions.
“Cognigy.AI‘s mix of advanced Conversational AI capabilities and leading ease-of-use makes it unique,” stated Philipp Heltewig, CEO and co-founder of Cognigy. “The pandemic has created urgency for businesses to accelerate their automation plans, and virtual agents have become a top priority. We are equipping enterprise contact centers with the technology they need to meet their customers where they are and start providing the best possible conversational experiences.”
Cognigy.AI v4 features include:
- Editing Experience - More intuitive to use; enables non-technical users to orchestrate sophisticated use cases with ease; increases governance and productivity
- Developer Experience - Improved enterprise-fit; shorter time-to-ROI; higher efficiency and granular control for developers
- Conversational Experience - Highest accuracy NLU; AI-assisted creation of intent model; better control and usability
- Voice Experience - A turnkey solution for Contact Center Automation
"We believe Cognigy.AI v4 to be the most comprehensive, user-friendly Conversational AI platform on the market today, which will empower our business users and developers for building advanced, multi-lingual virtual agents at scale," said Nick Allgaier, Project Lead at Lufthansa Group.
The use of virtual assistants, chatbots, and voice assistants make it possible to automate customer communications and personalize customer and employee experiences with minimal effort. Conversational AI uses messaging apps, chatbots, and phone lines to automate conversations between customers and your organization. Advanced virtual agents enable customers to accomplish their goals in a natural, human-like conversation. This helps provide a personalized customer experience and boost customer satisfaction.
To learn more about Cognigy.AI and Conversational AI Automation, visit cognigy.com .
Download media kit images here .
About Cognigy
Cognigy is a global leader in Conversational AI Automation. Its platform, Cognigy.AI, enables enterprises to automate customer and employee communications using intelligent voice- and chatbots. With precise, reliable intent recognition, highly flexible dialogs and seamless integration into backend systems, Cognigy.AI creates superior user experiences and helps companies reduce contact center costs and increase efficiency. Cognigy.AI is available in SaaS and on-premise environments and supports conversations in any language and on any channel including web, phone, SMS and mobile apps. Cognigy’s worldwide client portfolio includes Daimler, Bosch, Lufthansa, Salzburg AG and many more. Learn more at cognigy.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200901005304/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom